Do low‑nicotine e‑liquids lead to lower nicotine intake?
Developing Evidence To Inform Regulatory Policy On Nicotine Content In E-Liquids
This project looks at whether people who use lower‑nicotine e‑liquids actually take in less nicotine than those using higher‑nicotine e‑liquids.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rochester Institute of Technology NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11306615 on NIH RePORTER |
What this research studies
You would be one of 120 regular pod or pen‑style e‑cigarette users monitored in your normal daily life for one week. You would wear a small puff‑monitor that records every puff, and provide daily saliva (and some urine) samples to measure nicotine and other exposure biomarkers. The team will combine the puff‑by‑puff data with lab measurements of emissions from each product to estimate your real‑world nicotine and harmful constituent intake. They will also add pharmacokinetic analysis and symptom reports to better link behavior, product, and body exposure.
Who could benefit from this research
Good fit: Ideal participants are adult regular pod or pen‑style e‑cigarette users who currently use low‑ or high‑nicotine e‑liquids and can wear a puff monitor and provide daily saliva/urine samples for one week.
Not a fit: People who do not use e‑cigarettes, only vape very rarely, use very different devices (e.g., large mods), or cannot comply with wearing a monitor or providing samples are unlikely to benefit from participating.
Why it matters
Potential benefit: If successful, results could show whether switching to low‑nicotine e‑liquids actually reduces nicotine and harmful chemical exposure and inform safer product rules that protect users.
How similar studies have performed: Biomarker measures like salivary cotinine are well established for nicotine exposure, but combining real‑world puff tracking with product emissions and pharmacokinetics is a newer, less tested approach.
Where this research is happening
Rochester, United States
- Rochester Institute of Technology — Rochester, United States (Active)
Researchers
- Principal investigator: Robinson, Risa Jean — Rochester Institute of Technology
- Study coordinator: Robinson, Risa Jean
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.